New features provide real-time updates on the impact medical affairs teams are having on the HCP and HCO community to close clinical care gaps
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) — H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced new features and services to augment its AI-powered solution HCP Universe. HCP Universe serves as the leading source of truth on healthcare provider (HCP) information for more than 250 healthcare organizations, including top pharmaceutical companies looking to connect with thought-leading HCPs.
Evidence-based medicine (EBM) is the approach that patient care and clinical decisions should be informed by the best available and most recent scientific evidence gathered from clinical trials, along with clinical experience and patient preference. According to Johns Hopkins Medicine, evidence-based medicine is the cornerstone of clinical practice and can improve patient outcomes and quality of care. Yet, despite the benefits, adoption of evidence-based medicine remains low. HCP Universe will enable medical affairs teams to successfully engage HCPs and measure how their efforts are changing clinical behavior and improving patient outcomes.
“Evidence-based medicine is the discerning use of current best evidence in making decisions about the care of patients,” according to Dr. Rebecca Weintraub, Associate Professor at Harvard Medical School. “The practice of evidence-based medicine means integrating the best available clinical evidence with clinical expertise. This begins with stakeholder collaboration on how the evidence is compiled, shared and evaluated.”
Now, medical affairs teams can discover and interact with healthcare organizations with low adherence to evidence-based medicine; identify the HCPs that present the greatest opportunity for education; create a plan to educate them about the latest research and therapies; and map the impact of this work by tracking key performance indicators (KPIs) including share of scientific voice and sentiment.
H1’s advanced machine learning models drive predictive analytics and insights, enabling Medical Affairs teams to:
“Not only are we on a mission to connect the world with the right doctors, but we are also on a mission to improve adherence to evidence-based medicine,” said Ariel Katz, CEO and co-founder of H1. “We share this mission with our pharmaceutical clients – they want HCPs to follow guidelines-based medicine and adopt their therapies. We want the same because it will improve patient outcomes, quality of life, and access to equitable healthcare. By the end of 2024, we believe that companies using HCP Universe can increase adherence to evidence-based medicine by as much as 20%.”
HCP Universe harnesses the power of healthcare information to deliver 360-degree insights on more than 10 million HCPs and KOLs, their clinical and scientific work, industry collaborations, spheres of influence, and social media thought leadership. H1 works with over 250 leading healthcare companies globally including top pharma and supports projects across six continents.
Representatives from H1 will be at the upcoming MAPS 2023 Global Annual Meeting in Nashville, Tennessee, March 26-29. For more information on how H1 can help Medical Affairs track and measure impact, visit us here or to request a meeting with H1 during an upcoming conference, contact laura.girasole@h1.co.
About H1
H1 is the connecting force for global HCP, clinical, scientific, and research information. The H1 Connect platform democratizes access to HCP knowledge and groundbreaking insights for life sciences, academic medical institutions, health systems, and payors. H1 Connect fuels a robust product suite that helps customers discover and engage industry experts, drive equitable research, access groundbreaking science, and accelerate commercial success with the most robust and accurate healthcare professional data. Learn more at h1.co.
Media Contact:
Anya Nelson
Scratch Marketing + Media for H1
anyan@scratchmm.com
NEWARK, DE / ACCESSWIRE / November 22, 2024 / Laurel Bridge Software, a leader in…
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or…
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New…
Diarrhea is one of the most common reasons for veterinary visits for dogs and the…
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers…
FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the…